REGENXBIO Inc. (RGNX) News
Track canonical SquawkNews coverage tagged to RGNX, REGENXBIO Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 27 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RGNX: Late-stage gene therapy programs show strong efficacy, with pivotal data and regulatory filings imminent
The company is advancing late-stage gene therapy programs in DMD and ophthalmology, with RGX-202 showing strong efficacy and safety data and a BLA submission planned for early next year. Large pivotal trials in wet AMD a
NEWS | Sep 15, 2026, 02:02 PM UTC
L
RGNX: Late-stage gene therapy programs show strong efficacy, with financial runway into Q4 2027
The company is advancing late-stage gene therapy programs in DMD and retina, with RGX-202 showing strong efficacy and safety, and pivotal wet AMD trials with AbbVie targeting significant reduction in injection burden. Fi
NEWS | Sep 15, 2026, 01:24 PM UTC
L
REGENXBIO to participate in upcoming investor conferences
REGENXBIO said it will participate in the Baird 2026 Global Healthcare Conference and a Fireside Chat on Tuesday, September 15 at 8:30 a.m. ET in New York, NY.
EQUITY | Sep 08, 2026, 11:05 AM UTC
L
RGNX - REGENXBIO to Participate in Upcoming Investor Conferences
RGNX - REGENXBIO to Participate in Upcoming Investor Conferences
EQUITY | Sep 08, 2026, 11:05 AM UTC
L
REGENXBIO (RGNX) faces shareholder claims investigation by Johnson Fistel
Johnson Fistel, PLLP says it investigates claims on behalf of long-term shareholders of REGENXBIO Inc. (RGNX), according to TradeXchange Newsdesk.
REGULATION | Aug 25, 2026, 05:00 PM UTC
L
Regenxbio (RGNX) appoints Greg Ciongoli to strengthen board
Regenxbio appoints Greg Ciongoli to its board of directors, according to TradeXchange Newsdesk.
EQUITY | Aug 25, 2026, 11:05 AM UTC
M
RGNX falls 23% premarket on FDA headlines
RGNX shares fall 23% in premarket trading after FDA headlines, with no further catalyst provided in the wire.
REGULATION | Aug 24, 2026, 12:01 PM UTC
L
RGNX - REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
RGNX - REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
EQUITY | Aug 24, 2026, 11:06 AM UTC
L
Regenxbio and NS Pharma evaluate additional RGX-121 data
Regenxbio and NS Pharma are evaluating additional data for RGX-121, according to the market alert, with no catalyst or magnitude supplied.
EQUITY | Aug 24, 2026, 11:05 AM UTC
H
Regenxbio says FDA places clinical hold on RGX-121
Regenxbio says the FDA places a clinical hold on RGX-121 after spine MRI findings and does not expect to resubmit the RGX-121 BLA in the near term.
REGULATION | Aug 24, 2026, 11:05 AM UTC
L
RGNX RGNX - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
RGNX RGNX - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 06, 2026, 11:05 AM UTC
L
RGNX RGNX - REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Clic
RGNX RGNX - REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 03, 2026, 11:05 AM UTC
L
Deals priced today • CLBK (Columbia Financial) 167M share IPO, priced at $10.00, by KBW, Piper & Brean • RGNX 10M share Spot Secondary, pric
Deals priced today • CLBK (Columbia Financial) 167M share IPO, priced at $10.00, by KBW, Piper & Brean • RGNX 10M share Spot Secondary, priced at $9.00, by MSCO, JPMC, Leerink & Mizuho Deal to be priced • RPT Secondary a
EQUITY | Jul 17, 2026, 12:26 PM UTC
H
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 2% on Friday. Shares of Intuitive Surgical Inc (NASDAQ: ISRG ) fell sharply in pre-market trading after the company reported second-q
EARNINGS | Jul 17, 2026, 12:02 PM UTC
L
RGNX -17% premarket after offering headlines
RGNX -17% premarket after offering headlines
EQUITY | Jul 17, 2026, 11:18 AM UTC
H
Market-Moving News for July 17th
NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company narrowed its FY26 sales guidance with its midpoint be
EARNINGS | Jul 17, 2026, 11:16 AM UTC
L
RGNX Regenxbio announces pricing of public offering of common stock and pre-funded warrants Regenxbio - expects gross proceeds of about $100
RGNX Regenxbio announces pricing of public offering of common stock and pre-funded warrants Regenxbio - expects gross proceeds of about $100M from offering - Prices public offering of 10M shares at $9 and 1.11M pre-funde
EQUITY | Jul 17, 2026, 11:00 AM UTC
H
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Shares of Callan JMB Inc (NASDAQ: CJMB ) rose sharply in pre-market trading following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical ma
MACRO | Jul 17, 2026, 08:48 AM UTC
L
RGNX -12% post mkt after offering headlines
RGNX -12% post mkt after offering headlines
EQUITY | Jul 16, 2026, 08:29 PM UTC
L
RGNX Regenxbio announces proposed public offering of common stock
RGNX Regenxbio announces proposed public offering of common stock
EQUITY | Jul 16, 2026, 08:27 PM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
M
RGNX Completes Dosing
REGENXBIO completes dosing in its confirmatory study of RGX-202 gene therapy for Duchenne muscular dystrophy
EQUITY | Jun 24, 2026, 11:18 AM UTC
H
RGNX Completes Dosing
REGENXBIO completes dosing in confirmatory study of RGX-202, marking completion of registrational development program and supporting planned BLA submission in Q3 2026
EQUITY | Jun 24, 2026, 11:05 AM UTC
H
RGNX: FDA Reconsiders Gene Therapy
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy
EQUITY | Jun 22, 2026, 01:23 PM UTC
H
RGNX Seeks FDA Approval
REGENXBIO plans to resubmit its one-time gene therapy for Hunter Syndrome to the FDA after a path forward was established.
EQUITY | Jun 22, 2026, 11:35 AM UTC
H
RGNX Aligns with FDA
REGENXBIO announces alignment with FDA on path forward for NAVSUNLI BLA resubmission for accelerated approval
EQUITY | Jun 22, 2026, 11:31 AM UTC
H
RGNX: FDA Reverses Rejection
Regenxbio says FDA will reverse rejection of third rare-disease drug
EQUITY | Jun 22, 2026, 10:41 AM UTC